The historical rank and industry rank for Thyrocare Technologies's OCF Margin % or its related term are showing as below:
NSE:THYROCARE'
s OCF Margin % Range Over the Past 10 Years
Min: 19.5 Med: 26.19 Max: 39.28
Current: 25.72
During the past 13 years, the highest OCF Margin % of Thyrocare Technologies was 39.28%. The lowest was 19.50%. And the median was 26.19%.
NSE:THYROCARE's OCF Margin % is ranked better than 87.19% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.67
vs NSE:THYROCARE: 25.72
Thyrocare Technologies OCF Margin % Related Terms
Thyrocare Technologies OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THYROCARE vs TMO, DHR, IDXX: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thyrocare Technologies (NSE:THYROCARE) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Thyrocare Technologies and its competitors. Over the past decade, Thyrocare Technologies' OCF Margin % has ranged from 19.50 to 39.28. According to the industry distribution chart, Thyrocare Technologies ranks #26 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 12.8%.
Is Thyrocare Technologies' OCF Margin % too high?
Thyrocare Technologies' current OCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 19.50 to a high of 39.28. Based on the distribution chart, Thyrocare Technologies ranks #26 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Thyrocare Technologies has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #26 out of 203 companies for OCF Margin %. This places Thyrocare Technologies in the top 13% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 4.67. Historically, Thyrocare Technologies' own OCF Margin % has ranged from 19.50 to 39.28 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.67, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Thyrocare Technologies and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thyrocare Technologies's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹392.93, compared to a current price of ₹543.40 — trading 38.3% above its estimated fair value. The current OCF Margin % is 0.00%. Thyrocare Technologies' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹543.40 is trading 38.3% above its estimated GF Value™ of ₹392.93.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
OCF Margin %: 0.00%
GF Value™: ₹392.93 vs. price of ₹543.40 (38.3% above fair value)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
87GF Score
Get the complete analysis for NSE:THYROCARE
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
